BioCorRx Inc (BICX)
OTHER OTC:BICX
Want to see BICX full AI Analyst Report?
BICX Stock Chart & Stats
$0.32
$0.00(0.00%)
At close: 4:00 PM EST
$0.32
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$0.20 - $0.50
Previous CloseN/A
Volume44.00
Average Volume (3M)824.00
Market Cap
$10.56M
Enterprise Value$6.50M
Total Cash (Recent Filing)$139.36K
Total Debt (Recent Filing)$2.13M
Price to Earnings (P/E)―
Beta0.72
Next Earnings
Aug 17, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.07
Shares Outstanding26,402,874
10 Day Avg. Volume1,315
30 Day Avg. Volume824
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)-0.48
Price to Sales (P/S)6.75
P/FCF Ratio-2.34
Enterprise Value/Market Cap0.62
Enterprise Value/Revenue8.15
Enterprise Value/Gross Profit9.40
Enterprise Value/Ebitda-2.67
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.21
Revenue Forecast (FY)$971.85K
Bulls Say, Bears Say
Bulls Say
Focused SUD Business ModelA concentrated business model in substance use disorder (SUD) and related behavioral health is structurally durable given persistent unmet treatment needs. Specialized offerings (medication-assisted treatment, patient management, affiliated clinical services) support differentiated clinical capabilities and longer customer relationships versus one-off services.
2025 Revenue ReboundA material revenue rebound in 2025 demonstrates the business can recover scale after setbacks, indicating underlying demand or improved commercialization. If sustained, higher revenue can enable operating leverage, improve unit economics and provide a pathway to stabilize margins over multiple quarters.
Subsidiary ReorganizationThe March 2026 stock-exchange reorganization centralizes control of the subsidiary under a tax-efficient structure while avoiding cash payments. This can increase strategic flexibility, simplify governance and preserve cash for operations — durable benefits for restructuring capital allocation and executing longer-term strategy.
Bears Say
Very Weak Balance SheetA persistently negative equity base materially limits financial flexibility and increases refinancing risk. With an equity deficit and elevated leverage the company has less capacity to absorb operational shocks, hindering investment in growth and raising the probability of dilutive financings or distressed transactions.
Chronic Cash BurnConsistent negative operating and free cash flow forces reliance on external capital to sustain operations. Over time this pattern elevates dilution and refinancing risk, constrains the ability to fund organic growth or marketing, and limits strategic optionality absent a durable shift to positive cash generation.
Deep Unprofitability & Weak EconomicsLarge recurring losses and a reported zero gross profit indicate the core economics are not yet viable. Persistent negative margins and volatile revenue make forecasting and scaling difficult, implying the company must materially improve margins or revenue quality to achieve sustainable profitability.
BioCorRx News
BICX FAQ
What was BioCorRx Inc’s price range in the past 12 months?
BioCorRx Inc lowest stock price was $0.20 and its highest was $0.50 in the past 12 months.
What is BioCorRx Inc’s market cap?
BioCorRx Inc’s market cap is $10.56M.
When is BioCorRx Inc’s upcoming earnings report date?
BioCorRx Inc’s upcoming earnings report date is Aug 17, 2026 which is in 108 days.
How were BioCorRx Inc’s earnings last quarter?
BioCorRx Inc released its earnings results on Aug 14, 2025. The company reported -$0.07 earnings per share for the quarter, the consensus estimate of -$0.07 by $0.
Is BioCorRx Inc overvalued?
According to Wall Street analysts BioCorRx Inc’s price is currently Overvalued.
Does BioCorRx Inc pay dividends?
BioCorRx Inc does not currently pay dividends.
What is BioCorRx Inc’s EPS estimate?
BioCorRx Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does BioCorRx Inc have?
BioCorRx Inc has 26,402,874 shares outstanding.
What happened to BioCorRx Inc’s price movement after its last earnings report?
BioCorRx Inc reported an EPS of -$0.07 in its last earnings report, expectations of -$0.07. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of BioCorRx Inc?
Currently, no hedge funds are holding shares in BICX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
BioCorRx Inc
BioCorRx Inc., through its subsidiaries, develops and provides treatment programs for substance abuse and related disorders in the United States. It distributes and licenses BioCorRx recovery program, a non-addictive and medication-assisted treatment program that includes a counseling program coupled with its proprietary naltrexone implant; and distributes UnCraveRx weight loss management program, a medically assisted weight management program to reduce food cravings combined with on-demand virtual lifestyle support, fitness, and nutrition. The company is also developing BICX101, an injectable naltrexone product; and BICX104, an implantable naltrexone implant for the treatment of opioid addiction and alcoholism. It distributes its program to healthcare providers, independent licensed clinics, and licensed healthcare professionals. The company was formerly known as Fresh Start Private Management, Inc. and changed its name to BioCorRx Inc. in January 2014. BioCorRx Inc. is based in Anaheim, California.
Technical Analysis
American Shared Hospital Services
―
Concord Medical Services
―
Cryo-Cell International
―
Oncology Institute
―
COMPASS Pathways
―